.png){kind=logo}
To support innovative and strategic drug development.
Ask our experts
JC Discovery® offers the combination of predictive preclinical models and innovative translational services that originate from its two founding entities, the Center of Immunophenomics (CIPHE; INSERM, CNRS, AMU) and Janvier Labs, both located in France.
The unique JC Discovery® knowledge environment offers a comprehensive range of services permitting to develop in vitro and in vivo gene-edited preclinical models and to characterize the mouse, rat, and human immune systems using high-content immune-profiling.
At JC Discovery®, we support pharma and biotech strategic drug development in the field of immuno-oncology, inflammation, and auto-immune diseases.
With academic connections, know-how, state-of-the-art technology platforms, and integrated data analysis, JC Discovery® also developed an innovative Fast-TrackTM pipeline based on primary human T-cells and omics, aiming at identifying, validating and prioritizing drug targets and at elucidating the mechanisms of action of new innovative immuno-therapeutics.
With decades of academic expertise leading successful translational projects and partnering with major public institution teams and private pharmaceutical companies, JC Discovery® has made innovation the corner-stone to advance new therapeutics from discovery, preclinical to move them efficiently to clinical stage of development.
JC Discovery® develops new translational approaches using primary human T-cells aiming at identifying, validating, and prioritizing drug targets and at elucidating the mechanisms of action of new innovative immunotherapeutic drugs.
.png)
JC Discovery® is committed to scientific excellence, R&D expertise to bringing our customers the best chance of success to develop their innovative therapeutics.
With over 60 years' experience, our Team provides high added value to researchers to to give the best chance of success to their R&D programs.
JC Discovery® is committed to delivering the highest level of client satisfaction from the initial phase of project strategy to the delivery of your models and research programs results.
JC Discovery® scientists have and extensive expertise in the discovery and pre-clinical validation of the efficacy and the mechanism of action of immune-related therapeutics. We are eager to share our scientific knowledge with academia, biotechs, pharma, and scientific organizations world-wide to stimulate and help innovative therapeutic developments.
.png)
Co-founder
Chief Executive Officer, Group
.png)
Chief Executive Officer MiMabs,
JC Discovery and Xentech
.png)
Co-founder
Chief Scientific Officer, Group
.png)
Scientific Advisor
.png)
Co-founder, Scientific Director and Operation Coordinator
.png)
Co-founder
Scientific Advisor, Fast-Track Design
.png)
Co-founder, Scientific Advisor, Fast-Track Immunomics
.png)
Study Director
.png)
Study Director
.png)
Business Developer Immuno-Oncology, JC Discovery and MiMabs
JC Discovery® benefits from multiple connections with industrial and academic players like the Institute Curie. The network of academic research institutions partnering with JC Discovery® also includes the Center of Immunophenomics (CIPHE) and the Center of Immunology Marseille - Luminy (CIML).
With Mérieux Equity Partners, the newly created Group, including JC Discovery® aims at creating a world leader in translational research, by pursuing the development of its offer of innovative research models with high added value services. This support allows to develop further innovation to bring solutions to the emergingcustomers needs of high value in vitro and in vivo models, together with early preclinical services.
By forging alliances with academic and industry partners, JC Discovery® stands on bold research to fulfill its mission:
advancing the development and understanding of the mechanism of action of breakthrough immune-related therapies.
Very short description here.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
